24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in most…
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Wednesday's top analyst upgrades, downgrades and initiations included Biogen, Coca-Cola, Crowdstrike, Kohl’s, ServiceNow, Snap and Travelers.
Biogen released its third-quarter financial results and Alzheimer’s trial news before the markets opened on Tuesday.
Chris Lange Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Friday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Alphabet, Altria, Amazon.com, Boeing, Caterpillar, Chipotle Mexican Grill, E*Trade, Gap, Snap and Twitter.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The September 30 short interest data has been compared with the previous report, and short interest in most…
The September 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The August 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The August 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
